Related Experiment Video

Updated: Jun 17, 2026

Multiplex Cytokine Profiling of Stimulated Mouse Splenocytes Using a Cytometric Bead-based Immunoassay Platform
11:00

Multiplex Cytokine Profiling of Stimulated Mouse Splenocytes Using a Cytometric Bead-based Immunoassay Platform

Published on: November 9, 2017

Kitasato symposium 2009: new prospects for cytokine inhibition

Gerd R Burmester1, Peter E Lipsky, Thomas Dörner

  • 1CC12, Charite Universitätsmedizin Berlin, Chariteplatz 01, 10098 Berlin, Germany. gerd.burmester@charite.de

Arthritis Research & Therapy
|January 14, 2010
PubMed

Insights

This 2009 symposium focused on cytokine inhibition for autoimmune diseases like rheumatoid arthritis. Researchers evaluated cytokine blockade and their role in disease pathogenesis and immune system interactions.

Area of Science:

  • Immunology
  • Rheumatology
  • Molecular Biology

Background:

  • The Kitasato Symposium 2009 convened experts to discuss cytokine inhibition in autoimmune diseases.
  • Key focus areas included rheumatoid arthritis pathogenesis and cytokine blockade strategies.

Framework:

  • The symposium evaluated the role of specific cytokines in immune system interactions.
  • Discussions covered cytokine involvement in joint destruction and regulation of T and B cells.

Implementation:

  • A keynote lecture by Professor Jean-Michel Dayer provided insights into immune system and acute phase protein interactions.
  • Presentations addressed the application of cytokine inhibition in managing autoimmune conditions.

Implications:

  • Understanding cytokine roles advances therapeutic strategies for rheumatoid arthritis and other autoimmune disorders.
  • This research highlights the potential of cytokine blockade in treating immune-mediated diseases.

More Related Videos

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...